目的 调研2015年10月1日~2016年3月31日在某三甲医院内分泌科住院的糖尿病患者阿司匹林的使用情况,分析其用药合理性,为促进临床合理使用该药提供参考。方法 根据相关指南及文献等,分析其用药的适宜性;通过观察患者院内不良反应的发生情况,分析其用药的安全性。结果 本研究共纳入204例患者。按照指南,对已发生过心血管疾病或有高危心血管风险的患者均应使用阿司匹林,但此次研究中,这两类患者阿司匹林的实际使用率为62.50%;阿司匹林肠溶片按说明书应餐前服药,但住院患者仍有约23%的医嘱为餐后服药;多位患者的医嘱中均有药物与阿司匹林存在相互作用,但临床治疗中并未观察到不良事件;院内使用阿司匹林的患者发生不良反应的比例仅有1.83%。结论 住院患者使用阿司匹林的适宜性有待进一步提高;患者使用日剂量100 mg阿司匹林的安全性较好。
Abstract
OBJECTIVE To investigate the use of aspirin in patients hospitalized in department of endocrinology from October 1st, 2015 to March 31th, 2016 and analyze the rationality use of aspirin to promote the proper use. METHODS The appropriateness of aspirin use was analyzed according to relevant guidelines, literature etc. And the safety was analyzed through observing the incidence of adverse drug reaction(ADR). RESULTS The 204 patients were included. For patients with cardiovascular disease or with high cardiovascular risk, aspirin should be used according to guidelines. But the actual utilization rate of aspirin was 62.50% in these two kinds of patients. About 23% of patients used aspirin after a meal which should be used on an empty stomach based on instruction. Although these patients used some drugs that could interact with aspirin, no adverse events observed during hospitalization. For inpatients who used aspirin, the proportion of ADR was only 1.83%. CONCLUSION Rational use of aspirin need to be further improved, the safety of 100 mg aspirin is good.
关键词
糖尿病 /
阿司匹林 /
合理性 /
适宜性 /
安全性
{{custom_keyword}} /
Key words
diabetes /
aspirin /
rationality /
appropriateness /
safety
{{custom_keyword}} /
中图分类号：
R969
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] TANG X M. The application of aspirin in cardiovascular disease [J]. Chin J Mod Drug App(中国现代药物应用),2010,4(5):119-120.
[2] ZHOU Y, BAO M L, HUANG S Q, et al. Analysis on aspirin use in patients with diabetes mellitus [J]. Guide China Med (中国医药指南),2012,10(16):176-177.
[3] WANG Y M, XIE W Z. Clinical application of aspirin in diabetes prevention [J]. Prog Pharm Sci(药学进展),2007,31(11):520-521.
[4] WANG X R, PEI Y, LI Q M, et al. Utilization of aspirin in patients with type 2 diabetes mellitus [J]. J China Pharm(中国药房), 2008,19(23):1774-1775.
[5] PENG W X, CHEN J H, MEI D, et al. Brief analysis of aspirin resistance and its implications [J]. Chin Pharm J(中国药学杂志),2017,52(14):1285-1290.
[6] TANTRY U S, BLIDEN K P, GURBEL P A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation [J]. J Am Coll Cardiol,2005,46(9):1705-1709.
[7] CHEN W H, CHENG X, LEE P Y, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease[J]. Am J Med,2007,120(7):631-635.
[8] Chinese Diabetes Society. China guideline for type 2 diabetes(2013 edition) [J]. Chin J Diabete(中华糖尿病杂志),2014,6(7):447-498.
[9] American Diabetes Association. Standards of medical care in diabetes—2016 abridged for primary care providers[J]. Clin Diabetes,2016,34(1):3-21.
[10] LUO W Y, TANG F M, WU J, et al. A survey on administration of aspirin for diabetic patients in a community hospital [J]. J Pract Med(实用医学杂志),2008,24(1):126-129.
[11] GOFF D C, LLOYD-JONES D M, BENNETT G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines[J]. J Am Coll Cardiol, 2014, 63(25 Pt B): 2935-2959.
[12] JI L W, XIE J, CAI Q, et al. Analysis of drug-drug interactions in prescriptions for hospitalized diabetic patients [J]. Chin Pharm J(中国药学杂志), 2014,49(11):944-947.
[13] GU Z, WANG J. Interactions between aspirin and other medicines [J]. Chin Hosp Pharm J(中国医院药学杂志),1996,16(10):455-457.
[14] LIU X Y. Analysis of aspirin withdrawal factors in patients with cardiovascular and cerebrovascular disease [J]. World Latest Med Inf(世界最新医学信息文摘),2015,15(7):109-110.
[15] WANG Z F, FENG R J, LI B, et al. Meta-analysis of aspirin in primary prevention of cardiovascular events in patients with diabetes[J]. J Qinghai Med Coll(青海医学院学报),2015,36(1):59-64.
[16] PATRONO C, GARCIA RODRIGUEZ L A, LANDOLFI R, et al. Low-dose aspirin for the prevention of atherothrombosis[J]. N Engl J Med, 2005,353:2373-2383.
[17] HERNANDEZ-DIAZ S, GARCIA RODRIGUEZ L A. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications[J]. BMC Med, 2006,4:22.
[18] GERSTEIN N S, SCHULMAN P M, GERSTEIN W H, et al. Should more patients continue aspirin therapy perioperatively?[J]. Ann Surg,2012,255(5):811-819.
[19] XIONG L, HE G Q, HOSPIEAL J C. The study of tooth extractions for patients taking aspirin for a long-term [J]. J Clin Stomatol(临床口腔医学杂志),2014, 30(7):419-420.
[20] LU M M, GAO Y M. Clinical effects of small doses of aspirin on socket bleeding in residual root extraction [J]. J Oral Maxillofacial Surgery(口腔颌面外科杂志),2013,23(1):42-45.
[21] LIU C A, YUAN M B. The study of gastrointestinal mucosal injury caused by aspirin [J]. Chin J Intern Med(中华内科杂志),1998,37(8):564-565.
[22] LIAN X F, XIANG D C. The effect on gastrointestinal side effects of enteric aspirin′s taking time [J]. Chin J Coal Ind Med(中国煤炭工业医学杂志),2005,8(5):457-458.
[23] MCALL N T, TOILER G H, SCHAFER A I, et al. Collaborative Meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients[J]. BMJ,2002(324):71-86.
[24] LU C L, GAO L L, SUN T, et al. The effect on TXA2 and PGI2 of low-dose aspirin′s different taking time[J]. Chin J Geriatr Heart Brain Vessel Dis(中华老年心脑血管病杂志),2003,5(4):267.
[25] WANG W, CHEN Y L, HOU X L, et al. Study on the influence of different aspirin′s taking time on patients with carotid plaque [J]. Chin Primary Health Care(中国初级卫生保健),2015,29(9):104-105.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1051 KB)
